Foslevodopa-foscarbidopa infusion
Duncan Street1, Lara Teare1, Andrea Lindahl1
1Department of Neurology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
Abstract:
Advanced Parkinson's disease poses numerous management challenges related to an increasingly inconsistent and unpredictable response to oral levodopa therapy, complicated by disabling motor and non-motor fluctuations and dyskinesias. Deep brain stimulation, levodopa-carbidopa intestinal gel and subcutaneous apomorphine are established non-oral treatments for advanced Parkinson's disease but delivery of these therapies is restricted to small numbers in specialist centres. Continuous subcutaneous foslevodopa-foscarbidopa infusion (CSFFI) therapy may address this unmet need. Here, we provide experience and practical insights from delivering a CSFFI service within the UK National Health Service. We highlight advantages of CSFFI vs alternative device-aided treatment options and outline a framework for starting and maintaining treatment, including managing common side effects, illustrated by patient cases.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Drug Dosing: Geriatric Patients
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Drug Dosing: Infants and Children
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...

![Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F67458.jpg&w=3840&q=50)
